Upregulation of DEAD box helicase 5 and 17 are correlated with the progression and poor prognosis in gliomas
Upregulation of DEAD box helicase 5 and 17 are correlated with the progression and poor prognosis in gliomas
复制标题
DEAD盒解旋酶5和17的上调与神经胶质瘤的进展和不良预后相关
DOI：
10.1016/j.prp.2020.152828
复制
发表时间：
2020-01-01
影响因子：
2.8
通讯作者：
Huang, Guanglong
中科院分区：
文献类型：
--
作者：
Luo, Qisheng;Que, Tianshi;Huang, Guanglong
最近的研究表明，Ddx 5和Ddx 17在肿瘤发生中起重要作用。然而，Ddx 5和Ddx 17在胶质瘤中的研究还很少。我们的研究探讨了它们在胶质瘤中的表达，并评估了其与临床因素和预后意义的关系。与正常脑组织相比，胶质瘤组织中Ddx 5和Ddx 17的表达均显著上调，且两者的表达呈正相关。免疫组化证实瘤周区Ddx 5和Ddx 17的表达低于核心区，但高于正常脑组织。Ddx 5和Ddx 17的高表达与WHO分级和组织学类型相关，且与胶质瘤患者的总生存率相关。此外，Ddx 5和Ddx 17的高表达预测放疗或化疗的高级别胶质瘤患者的临床生存时间较短。结论：过表达的Ddx 5和Ddx 17参与了胶质瘤患者的临床进展和不良预后，提示其上调可作为肿瘤诊断和预测胶质瘤患者生存期的可靠临床预测指标。
Recent researches indicated Ddx5 and Ddx17 play crucial roles in tumorigenesis. However, the study of Ddx5 and Ddx17 in glioma remains a little. Our study investigated their expression in glioma and evaluated its association with clinical factors and prognostic significance. The expression of Ddx5 and Ddx17 were both upregulated in glioma tissues compared to normal brain tissues, and a significant positive correlation between Ddx5 and Ddx17 expression was identified by statistical analysis. Immunohistochemical staining verified the expression of Ddx5 and Ddx17 in peritumoral zone was lower than that in core zone but higher than normal brain tissues. Moreover, the increased expression of Ddx5 and Ddx17 was markedly correlated with WHO Grade and histological type, and high Ddx5 and Ddx17 were found to be significantly associated with the worse overall survival of glioma patients. In additional, higher expression of both Ddx5 and Ddx17 predicted shorter clinical survival time for high-grade glioma patients with radiotherapy or with chemotherapy. In conclusion, over-expressed Ddx5 and Ddx17 are involved in the clinical progression and poor prognosis of glioma patients, suggesting that their upregulation can be used as a reliable clinical predictor for tumor diagnosis and to predict survival in patients with glioma.